Rodin Therapeutics

[Rodin Therapeutics @Rodintx]

We shared some exciting news this morning. Read the full announcement: https://t.co/Xl33Z9NCXa

[Rodin Therapeutics @Rodintx]

It was an honor to attend the Society for Neuroscience's 49th annual meeting alongside 30,000 peers from more than 70 countries. #SfN19 @SfNtweets

[Rodin Therapeutics @Rodintx]

The Rodin team will present our poster, "Characterization of an HDAC corepressor complex inhibitor for the treatment of FTD-GRN," at the @SfNtweets annual meeting. Join us on Monday, Oct. 21 at the Alzheimer's Disease and Strategies session. #SfN19

[Rodin Therapeutics @Rodintx]

Rodin CMO J. Michael Ryan and senior director of CNS research Berkley Lynch attended a FTD meeting hosted by @MDBRide4Rare and @BluefieldProj this week. It was great to discuss the latest in FTLD-GRN therapeutic development alongside families, companies, regulators and academics.

[Rodin Therapeutics @Rodintx]

Rodin collaborator Hayel Tuncel will be presenting [11C]UCB-J data at the @officialEANM Conference on Sunday. We are happy to help progress the science of synaptic density imaging and look forward to the discussions. #EANM19

[Rodin Therapeutics @Rodintx]

As our controller and director of Rodin's financial organization, Sari Epstein provides in-depth financial analyses and ensures the integrity of our information systems.

[Rodin Therapeutics @Rodintx]

We recently held a company retreat up in Stowe, VT to align on our goals and to do some outdoor team building. We are energized for a busy fall!

[Rodin Therapeutics @Rodintx]

Ajim Tamboli, our CFO, was a biotech investor, analyst and advisor before he co-founded Endurant Capital Management. His experience will help us advance our lead program and build our pipeline. Read more: https://t.co/mGdocXjnlm

[Rodin Therapeutics @Rodintx]

Tomorrow on World #Alzheimers Day, we unite with patients, families and organizations in the global movement to help those affected by Alzheimer's and other forms of dementia. Learn more: https://t.co/S2BqKfjkPb #LetsTalkAboutDementia

[Rodin Therapeutics @Rodintx]

Two of our team members were in New London, CT this weekend to participate in the local 2019 Walk to End Alzheimer’s. We are proud to take part in the fight to #ENDALZ and raise funds for #Alzheimers care, support and research. #Walk2EndAlz

[Rodin Therapeutics @Rodintx]

We are excited to attend the @Xconomy Awards tonight as a finalist for the Big Idea Award in recognition of our novel therapies that enhance synaptic integrity and safely upregulate genes crucial to learning and memory. #XconomyAwards

[Rodin Therapeutics @Rodintx]

We're pleased to join the @MorganStanley Global Healthcare Conference in New York today where our CEO Adam Rosenberg will present on our scientific and clinical progress and milestones.

[Rodin Therapeutics @Rodintx]

Nathan Fuller, our senior director of chemistry, will be sharing the story of the discovery of Rodin's HDAC-CoREST inhibitors at the 20th SCI/RSC Medicinal Chemistry Symposium in Cambridge, UK tomorrow. Meeting agenda: https://t.co/SUjlMbQdqo

[Rodin Therapeutics @Rodintx]

Our CEO Adam Rosenberg will present tomorrow at the 21st annual @HCWCO Global Investment Conference. We look forward to many productive conversations. Read more: https://t.co/k3R4OGpY1o #HCWCO

[Rodin Therapeutics @Rodintx]

Our team will be presenting at the 2019 @WellsFargo Healthcare Conference in Boston today. Join us for Rodin's company presentation and one-on-one meetings. #BiotechNews

[Rodin Therapeutics @Rodintx]

#ICYMI: We've officially settled into our Boston headquarters and look forward to many productive discussions in our new space! https://t.co/lvMCWbeGmB

[Rodin Therapeutics @Rodintx]

Michael C. Hewitt, our senior director of CMC & program management, will present on our approach to developing HDAC-CoREST inhibitors to treat neurodegenerative diseases at the @AmerChemSociety Fall National Meeting today in San Diego. Link to session: https://t.co/FZaAFls87m

[Rodin Therapeutics @Rodintx]

At Rodin, our science is personal. Learn more about how we are driven to improve the quality of life for people with #synaptopathies in memory of our loved ones: https://t.co/iVOk6635IG

[Rodin Therapeutics @Rodintx]

Nathan Fuller, senior director of chemistry, guided development of our lead compound, RDN-929, and co-authored our scientific paper demonstrating the efficacy of our highly selective CoREST-HDAC inhibitors in preclinical models. Read the paper: https://t.co/ml0VRntsPu

[Rodin Therapeutics @Rodintx]

Our own Nathan Fuller is presenting today at the Gordon Research Conference on Medicinal Chemistry on “Discovery of CoREST complex-selective HDAC inhibitors with pro-synaptic effects for the treatment of synaptopathies." More on the conference here: https://t.co/n67X8bFAQr